AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
Yahoo2 hours agoABBV
The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Amazon's diversified growth and AI push, AbbVie's pipeline, Alibaba's cloud gains and Lulu's improving margins shape these analyst picks.
Yahoo2 hours agoABBV
Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely
Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the wrong combination costs more than most people realize.
Yahoo3 hours agoABBV
AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma
AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...
Yahoo7 hours agoABBV
AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)
AbbVie is supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. Find out why ABBV stock is a Buy.
SeekingAlpha13 hours agoABBV
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story
AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]
Yahoo15 hours agoABBV
Top Analyst Reports for Amazon, AbbVie & Alibaba
Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.
Yahoo20 hours agoABBV
Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
Allergan Aesthetics, an AbbVie company, today unveiled the Layered Beauty: The New Aesthetic Mindset report, informed by research among more than 12,000 beauty-involved consumers across nine global markets, complemented by practitioner expertise and regional perspectives. The report provides a global perspective on the impact of cultural attitudes toward beauty and aging to evolve the aesthetic treatment landscape and offers healthcare providers new perspectives on the behaviors shaping today's
Yahoo2 days agoABBV
Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half
Johnson & Johnson's valuation is above historical averages, already pricing in competent execution. Find out why JNJ stock is a hold.
SeekingAlpha2 days agoABBV
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections reaching approximately US$40 billion by 2031 at a compound annual growth rate near 12 percent, and other forecasts running higher still over longer horizons. The drivers are structural: an aging population, rising disposable incomes, the normalizatio
Yahoo3 days agoABBV
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Yahoo3 days agoABBV
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier Calming Cream. The restorative moisturizer is designed to soothe skin while helping restore and fortify the delicate skin barrier.
Yahoo3 days agoABBV
This Popular Healthcare ETF Is Diluting Your Dividend Income
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.
Yahoo3 days agoABBV
Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
Yahoo4 days agoABBV
Oligomerix Appoints Biopharmaceutical Industry Veteran Cara Cassino, M.D. as Interim President and Chief Executive Officer
BRONX, N.Y., August 31, 2026--Cassino appointed Interim President and CEO of Oligomerix
Yahoo4 days agoABBV
AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will participate in a fireside chat at 9:15 a.m. Central time.
Yahoo4 days agoABBV
AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data
Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)
Benzinga8 days agoABBV
If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of $468.74 billion.
Benzinga9 days agoABBV
AbbVie Still Has Room To Run
AbbVie stock outlook: Skyrizi & Rinvoq fuel EPS growth as Humira declines. Forward P/E and PEG suggest undervaluation.
SeekingAlpha11 days agoABBV
Sanofi: Trump's Vaccine Policy Won't Break The Story
Sanofi stock faces temporary pressure after Trumpâs vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.
SeekingAlpha11 days agoABBV
AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026
AbbVie (NYSE: ABBV) unveiled new clinical data at the 2026 World Conference on Lung Cancer that covers several lung cancer programs across its pipeline. Key updates included efficacy and safety readouts for investigational therapies ABBV-1480, telisotuzumab adizutecan, and ABBV-706 in non small cell and small cell lung cancer. The company outlined an expanded set of ongoing lung cancer trials that it stated could reshape its future oncology portfolio and longer term growth profile. For...
Yahoo13 days agoABBV
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker ident
Yahoo14 days agoABBV
3 Unpopular Stocks That Deserve Some Love
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Yahoo14 days agoABBV
AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer
AbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer
Benzinga14 days agoABBV
Merck Stock Ran On A Checklist Published In Advance
The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.
Yahoo14 days agoABBV
Pfizer Stock Is A Race Between New Drugs And Old Patents
The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.
Yahoo14 days agoABBV
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300
Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.
Benzinga18 days agoABBV
Wolfe Research Upgrades AbbVie (ABBV)
Fintel21 days agoABBV
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]
Yahoo21 days agoABBV
Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?
The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]
Yahoo21 days agoABBV
Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D […]
Yahoo21 days agoABBV
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
Yahoo22 days agoABBV
Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target
Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.
Benzinga22 days agoABBV
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.
Yahoo22 days agoABBV